HealthCare Royalty Partners
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From HealthCare Royalty Partners
Public Company Edition: The stock market has been unkind to biotech firms but investors rewarded some drug developers for clinical trial successes, including Scholar Rock and Day One, which raised $205m and $172.5m, respectively. However, some SPAC deals and an IPO never got off the ground.
Two days before flooding closed its Sturgis plant, Abbott announced it would import 1.1m pounds of powder formula to the US from its manufacturing facility in Spain.
The company got FDA approval for the drug in Bardet-Biedl syndrome, on top of the existing approval from November 2020 in obesity due to POMC, PCSK1 and LEPR deficiency.
Abbott's s Christopher Calamari, Gerber's Scott Fitz and Reckitt Robert Cleveland didn't have ng answers about immediately solving supply shortage or about preventing another one when they testified before Oversight and Investigation Subcommittee.